Financials Arecor Therapeutics plc

Equities

AREC

GB00BMWLM973

Biotechnology & Medical Research

Market Closed - London S.E. 11:35:03 2024-02-21 am EST 5-day change 1st Jan Change
147.5 GBX -2.64% Intraday chart for Arecor Therapeutics plc -5.75% -19.18%

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025
Capitalization 1 111.3 73.48 46.4 46.4 -
Enterprise Value (EV) 1 93.02 60.68 40.23 44.32 46.5
P/E ratio -14.8 x -7.5 x -6.31 x -7.05 x -16.8 x
Yield - - - - -
Capitalization / Revenue 96.1 x 30.6 x 9.26 x 6.12 x 3.72 x
EV / Revenue 80.3 x 25.3 x 8.03 x 5.85 x 3.73 x
EV / EBITDA -14.8 x -5.9 x -5.63 x -8 x -19.6 x
EV / FCF - -5.48 x -6.52 x -12.1 x -
FCF Yield - -18.3% -15.3% -8.28% -
Price to Book - 4.21 x 4.06 x 5.96 x -
Nbr of stocks (in thousands) 27,835 30,618 30,627 30,627 -
Reference price 2 4.000 2.400 1.515 1.515 1.515
Announcement Date 4/25/22 4/20/23 - - -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net sales 1 - 1.158 2.403 5.01 7.582 12.46
EBITDA 1 - -6.268 -10.29 -7.146 -5.539 -2.37
EBIT 1 - -6.439 -10.63 -8.181 -6.679 -
Operating Margin - -556.04% -442.36% -163.28% -88.09% -
Earnings before Tax (EBT) 1 - -6.945 -10.54 -7.813 -6.696 -3.29
Net income 1 -2.752 -6.169 -9.26 -6.904 -6 -2.63
Net margin - -532.73% -385.35% -137.81% -79.13% -21.11%
EPS 2 -1.020 -0.2700 -0.3200 -0.2400 -0.2150 -0.0900
Free Cash Flow 1 - - -11.08 -6.171 -3.67 -
FCF margin - - -461.05% -123.16% -48.4% -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 - - - - - -
Announcement Date 7/1/21 4/25/22 4/20/23 - - -
1GBP in Million2GBP
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - - - 0.1
Net Cash position 1 - 18.3 12.8 6.17 2.08 -
Leverage (Debt/EBITDA) - - - - - -0.0422 x
Free Cash Flow 1 - - -11.1 -6.17 -3.67 -
ROE (net income / shareholders' equity) - - - - - -
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share 2 - - 0.5700 0.3700 0.2500 -
Cash Flow per Share 2 - -0.2400 -0.3700 -0.2100 -0.1200 -0.0800
Capex 1 - 0.07 0.3 0.21 0.22 0.2
Capex / Sales - 5.96% 12.44% 4.19% 2.95% 1.61%
Announcement Date 7/1/21 4/25/22 4/20/23 - - -
1GBP in Million2GBP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.515 GBP
Average target price
4.71 GBP
Spread / Average Target
+210.89%
Consensus

Annual profits - Rate of surprise

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer